Sea cucumber peptide applied to auxiliary protection of acute gastric mucosal lesion and preparation method of sea cucumber peptide

Abstract

The invention discloses a sea cucumber peptide applied to auxiliary protection of acute gastric mucosal lesion and a preparation method thereof, and relates to the technical field of biological peptides, and the preparation method comprises the following steps: step 1, taking fresh sea cucumbers, and sequentially carrying out cleaning, acid-base soaking for ash removal and pulping treatment to obtain ground sea cucumber pulp; step 2, boiling the ground sea cucumber slurry at constant temperature and constant pressure, cooling to 55 DEG C, and performing enzymolysis by multiple compound enzymes to obtain enzymatic hydrolysate; step 3, heating the enzymatic hydrolysate to 85 DEG C and carrying out enzyme deactivation treatment for 5 minutes to obtain a protein peptide mixed solution; and 4, separating the protein peptide, and drying to obtain the sea cucumber peptide particles. The sea cucumber peptide applied to auxiliary protection of acute gastric mucosal lesion is obtained, it is detected that interleukin 1 beta (IL-1beta), interleukin 6 (IL-6), pepsinogen 1 (PG1), pepsinogen 2 (PG2) and tumor necrosis factor alpha (TNF-alpha) in rat serum have significant differences from a control group, and the purpose of auxiliary protection of acute gastric mucosal lesion is achieved.

Description

Technical Field

[0001] The present application relates to the field of biological peptide technology, and in particular to a sea cucumber peptide used for auxiliary protection of acute gastric mucosal injury and a preparation method thereof. Background Art

[0002] Sea cucumber peptide is a nutrient extracted from sea cucumbers. It has multiple functions and effects such as protecting cardiovascular and cerebrovascular vessels and anti-oxidation.

[0003] Acute gastric mucosal injury, also known as "stress mucosal lesions", is often seen in severe trauma, complex surgery and critical illness. The mechanism of occurrence is that under severe stress, lesions such as erosion, ulcers and bleeding of the digestive tract mucosa occur, which can cause digestive tract perforation in severe cases. Taking supplements containing bioactive peptides to nourish the intestines and prevent the occurrence of diseases such as acute gastric mucosal injury is a feasible way to maintain health.

[0004] A Chinese patent with announcement number CN118667908B discloses a high-calcium, high-protein sea cucumber peptide and a preparation method thereof. The preparation method of the high-calcium, high-protein sea cucumber peptide comprises the following steps: S11. pretreatment, S12. enzymatic hydrolysis, S13. auxiliary agent-assisted extraction, S14. heating to inactivate enzymes, S15. separation and purification, and S16. concentration and drying.

[0005] A Chinese patent application document with publication number CN104738699A discloses a sea cucumber peptide and a preparation method thereof. The preparation method of the sea cucumber peptide comprises the following steps: (1) adding composite protein zinc to sea cucumber liquid, stirring, and then adding trypsin and stirring; (2) heating to 40°C to 50°C, adjusting the pH value to 7 to 9, and reacting at a temperature of 40°C to 50°C for 4 to 8 hours to obtain a mixture; (3) adding edible alcohol with a concentration of 75% to 95% to the mixture described in step 2, stirring, and freeze-polymerizing at -20°C to 20°C for 5 to 15 hours until the mixture has solid-liquid stratification; and (4) centrifuging and drying the solid precipitate in the mixture to obtain the sea cucumber peptide.

[0006] However, the high-calcium and high-protein sea cucumber peptide prepared by the preparation method of the high-calcium and high-protein sea cucumber peptide and the sea cucumber peptide prepared by the preparation method of the sea cucumber peptide cannot be used for auxiliary protection of acute gastric mucosal injury, and need to be improved. Summary of the invention

[0007] In view of this, the first purpose of the present application is to provide a method for preparing sea cucumber peptides for auxiliary protection of acute gastric mucosal damage, so as to achieve the purpose of auxiliary protection of acute gastric mucosal damage. The specific scheme is as follows:

[0008] A method for preparing sea cucumber peptide for auxiliary protection of acute gastric mucosal injury comprises the following steps:

[0009] Step 1, taking fresh sea cucumbers, washing, acid and alkali soaking, deashing and grinding treatment in sequence, to obtain sea cucumber grinding liquid;

[0010] Step 2, boiling the sea cucumber grinding liquid at a constant temperature and pressure, cooling it to 55° C., and then performing enzymolysis with multiple complex enzymes to obtain an enzymolysis liquid;

[0011] Step 3, heating the enzymatic hydrolyzate to 85°C and performing enzyme inactivation treatment for 5 minutes to obtain a protein peptide mixture;

[0012] Step 4: Separate the protein peptides and obtain sea cucumber peptide particles by drying

[0013] Preferably: the cleaning is performed by washing with clean water, the acid-base deashing is performed by an activated carbon acid-base deashing process, and the refining is performed by grinding with a grinder.

[0014] Preferably, the multiple complex enzyme comprises neutral protease, papain and trypsin; and the added mass ratio of the neutral protease, papain and trypsin is 0.6-1:1.2-2:1.

[0015] Preferably: the separation of proteases comprises separating protein peptides using a high-speed bedroom centrifuge.

[0016] Preferably, the separation of protease also includes using a ceramic primary filtration membrane to coarsely filter visible solids and using an ultrafiltration membrane to separate macromolecular protein peptides.

[0017] Preferably, the separation of protease and drying also include fermentation to remove fishy smell, heavy metal removal, desalination, small molecule peptide separation, decolorization and concentration treatment in sequence.

[0018] Preferably: the fermentation to remove fishy smell is carried out by adopting a flavor fermentation process; the heavy metal removal and desalination are carried out by adopting an electrodialysis device to separate heavy metals and salts based on the electric field force or by adopting an ion exchange resin to remove heavy metals; the small molecule peptide separation is carried out by adopting an inorganic nanofiltration membrane to separate small molecule peptides below 1000DA; the decolorization is carried out by physical decolorization using a nanofiltration membrane; the concentration is carried out by adopting a double-effect tank concentration, and the drying is carried out by adopting a centrifugal pressure spray drying tower to carry out low-temperature spray drying.

[0019] The second purpose of the present invention is to provide a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury, which is prepared by the preparation method of sea cucumber peptide for auxiliary protection of acute gastric mucosal injury as described above, and is used for auxiliary protection of acute gastric mucosal injury.

[0020] Preferably: the relative molecular mass of the amino acid sequence of the sea cucumber peptide is 568.1.

[0021] Through the above scheme, it can be known that the present application provides a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury and a preparation method thereof. The sea cucumber peptide for auxiliary protection of acute gastric mucosal injury prepared by the preparation method of the sea cucumber peptide for auxiliary protection of acute gastric mucosal injury is based on the established acute gastric mucosal injury alcohol model, and the interleukin 1β (IL-1β), interleukin 6 (IL-6), pepsinogen 1 (PG1), pepsinogen 2 (PG2) and tumor necrosis factor α (TNF-α) in the rat serum are detected and obtained. There are significant differences with the control group. At the same time, through the influence on the incidence, integral index and inhibition rate of gastric mucosal injury in rats and the pathological section observation of gastric mucosal tissue, it can be seen that the sea cucumber peptide for auxiliary protection of acute gastric mucosal injury has an improvement effect on gastric mucosal injury in alcohol model rats, and the auxiliary protection function test results of gastric mucosal injury in alcohol model rats are positive, so the obtained sea cucumber peptide has an auxiliary protection function for gastric mucosal injury in alcohol model rats. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying any creative work.

[0023] Figure 1 Schematic diagram of the effect of the samples in this application on gastric mucosal injury in rats with acute alcohol model;

[0024] Figure 2 Schematic diagram of the effect of the samples in this application on the morphological changes of gastric mucosal tissue in rats with acute alcohol model. DETAILED DESCRIPTION

[0025] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0026] It should be mentioned that the experimental animals used in the examples of the present application are SPF-grade SD male rats, provided by Sibeifu (Suzhou) Biotechnology Co., Ltd. (license number is SCXK (Beijing) 2022-0006). The abalone peptide obtained for assisting lactation is a white powder and is stored in a cool, dark and dry place.

[0027] In order to evaluate the functional application of sea cucumber peptides for auxiliary protection of acute gastric mucosal injury, healthy male rats were used as subjects, and acute gastric mucosal modeling and experiments were performed in male rats. The gastric morphology and histopathology of male rats were measured, and the test results of biochemical indicators in serum were combined to complete the pathological diagnosis of rat gastric mucosa.

[0028] The following is a detailed description of a sea cucumber peptide used for auxiliary protection of acute gastric mucosal injury and a preparation method thereof.

[0029] A method for preparing sea cucumber peptide for auxiliary protection of acute gastric mucosal injury comprises the following steps:

[0030] Step 1, taking fresh sea cucumbers, washing, acid and alkali soaking, deashing and grinding treatment in sequence, to obtain sea cucumber grinding liquid;

[0031] Step 2, boiling the sea cucumber grinding liquid at a constant temperature and pressure, cooling it to 55° C., and then performing enzymolysis with multiple complex enzymes to obtain an enzymolysis liquid;

[0032] Step 3, heating the enzymatic hydrolyzate to 85°C and performing enzyme inactivation treatment for 5 minutes to obtain a protein peptide mixture;

[0033] Step 4: Separate the protein peptides and obtain sea cucumber peptide particles by drying

[0034] Among them, the cleaning is done by washing with clean water, the acid-base soaking and deashing is done by using an activated carbon acid-base deashing process, and the refining is done by grinding with a grinder. The above process steps are all conventional processes and will not be described in detail here.

[0035] It should be noted that the multiple complex enzyme includes neutral protease, papain, and trypsin, and the mass ratio of neutral protease, papain, and trypsin added is 0.6-1:1.2-2:1. In the embodiment of the present application, the mass ratio used is 0.6:1.2:1.

[0036] At the same time, the separation of protease includes the use of a high-speed bedroom centrifuge to separate protein peptides. Of course, in order to further improve the purity of the separation, it also includes the use of a ceramic primary filtration membrane to coarsely filter visible solids and the use of an ultrafiltration membrane to separate large molecular protein peptides. And by using fermentation to remove fishy smell, remove heavy metals, desalt, separate small molecule peptides, decolorize and concentrate in sequence between the separation of protease and drying, high-purity sea cucumber peptides for auxiliary protection of acute gastric mucosal damage are obtained.

[0037] Among them, fermentation to remove fishy smell adopts flavor fermentation process. Heavy metal removal and desalination adopt electrodialysis equipment to separate heavy metals and salts based on electric field force or use ion exchange resin to remove heavy metals. Small molecule peptide separation adopts inorganic nanofiltration membrane to separate small molecule peptides below 1000DA. Decolorization adopts nanofiltration membrane for physical decolorization. Concentration adopts double-effect tank concentration, and drying adopts centrifugal pressure spray drying tower for low-temperature spray drying.

[0038] A sea cucumber peptide for auxiliary protection of acute gastric mucosal injury is prepared by the above-mentioned preparation method of sea cucumber peptide for auxiliary protection of acute gastric mucosal injury, and is used for auxiliary protection of acute gastric mucosal injury. The relative molecular mass of the amino acid sequence of the obtained sea cucumber peptide is 568.1.

[0039] Functional application testing:

[0040] Rearing conditions: Experimental animals were reared in the barrier facility SYXK(Su)2021-0056 of the Experimental Animal Center of Jiangnan University at a temperature of 20-26°C and a relative humidity of 40-70%. Irradiated sterilized feed and bedding were provided by Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd., Su Feed Certificate (2019)01008.

[0041] Experimental Animals - Male rats were randomly divided into 5 groups according to body weight: blank control group, model control group and 3 sample groups of low, medium and high doses, and each sample group had 10 male rats.

[0042] Test items: gastric morphology measurement, histopathological observation, serum biochemical indicators.

[0043] Gastric morphology measurements - length and width of bleeding spots or bands.

[0044] Histopathological observation: The total score of the lesion was calculated based on the presence of congestion, hemorrhage, and mucosal cell degeneration and necrosis in the entire mucosal epithelium.

[0045] Serum biochemical indicators - detection of PG1, PG2, TNF-α, IL-1β and IL-6 levels in serum.

[0046] The test objects are divided into Example 1, Example 2, Example 3, Comparative Example 1 and Comparative Example 2. Example 1, Example 2 and Example 3 correspond to the low-dose group, medium-dose group and high-dose group in the acute gastric mucosal modeling test of male rats, respectively. Comparative Example 1 corresponds to the blank control group in the acute gastric mucosal modeling test of male rats, and Comparative Example 2 corresponds to the model control group in the acute gastric mucosal modeling test of male rats.

[0047] The specific experimental steps are as follows:

[0048] (1) In addition to the blank control group rats given distilled water, each dose group was given a sample aqueous solution of the corresponding content (low dose 0.25 g / kg BW, medium dose 0.50 g / kg BW, high dose 1.00 g / kg BW), and the intragastric volume was calculated as 10 mL / kg·BW;

[0049] (2) After oral gavage of the test sample group for 30 days, all rats were strictly fasted for 24 hours (but not water). Except for the blank control, all experimental group animals were given 1 mL of anhydrous ethanol per animal, and the animals were killed 1 hour later for the detection of various indicators and pathological histological examination;

[0050] (3) After the animals were killed, blood was collected from the heart strictly according to the time and batch. The whole blood samples were grouped and numbered and placed in 1.5 mL centrifuge tubes. After refrigeration in an ice machine for 30 minutes, low-temperature centrifugation was set at 3500r / min for 15 minutes to collect serum; the whole stomach was exposed, the pylorus was ligated, and an appropriate amount of 10% paraformaldehyde was perfused for fixation;

[0051] (4) The levels of PG1, PG2, TNF-α, IL-1β, and IL-6 in rat serum were detected using a kit method;

[0052] (5) After the gastric tissue is removed, it is cut open along the greater curvature of the stomach, the gastric contents are washed, the gastric mucosa is spread out, and the length and width of the bleeding point or bleeding band are measured under a stereoscopic dissection microscope. Because the severity of the injury represented by the width is much greater than the length, double points are assigned. The scoring criteria are shown in Table 1 below.

[0053] Table 1. Gross observation scoring criteria for acute anhydrous ethanol injury

[0054]

[0055] (6) After the gross examination, the most severely damaged part of the gastric mucosa of each animal was excised, fixed in 10% formaldehyde solution, routinely prepared, HE stained, and observed under a microscope. Pay attention to selecting the cross-sectional view of the gastric mucosa, including the entire layer of the mucosa for observation. Scoring method: The whole mucosal epithelial layer is divided into 5 levels according to the degree of involvement of congestion, hemorrhage, and mucosal cell degeneration and necrosis. The weight of congestion is 1, the weight of hemorrhage is 2, and the weight of epithelial cell degeneration and necrosis is 3. The scoring criteria and the total score formula of the lesion are shown in Table 2.

[0056] Table 2 Scoring criteria for histopathological examination of acute gastric mucosal injury

[0057]

[0058] Specifically, the difference between Examples 1-3 and Comparative Example 1 is the difference in the concentration of the test sample aqueous solution in step (1), and the difference between Examples 1-3 and Comparative Example 2 is the difference in the test sample in step (1); the results are shown in Table 3-5:

[0059] Table 3 Effects of samples on various indicators in mouse liver

[0060]

[0061] Note: **P<0.01, compared with the model control group.

[0062] As shown in Table 3, compared with the blank control group, the model control group had significant differences in interleukin 1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), pepsinogen 1 (PG1) and pepsinogen 2 (PG2) in the mouse serum (p < 0.01), indicating that the model was established. After 30 days of oral administration of the sample, compared with the model control group, the inflammatory factors interleukin 1β (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) in the three dose groups of the test substance were significantly different (p < 0.01), and there was a certain dose dependence, indicating that the sample can reduce the levels of IL-1β, IL-6 and TNF-α in rats with gastric mucosal injury, suggesting that the sample can improve the inflammatory response of rats with gastric mucosal injury.

[0063] Pepsinogen 1 (PG1) can reflect the secretory function of the gastric mucosa, and pepsinogen 2 (PG2) can reflect the secretory function of the entire gastric mucosa. Compared with the model control group, pepsinogen 1 (PG1) in the three dose groups of the test substance was significantly reduced (p < 0.05), and pepsinogen 2 (PG2) in the high dose group was significantly reduced (p < 0.01. This shows that the sample can reduce the PG1 level of rats with gastric mucosal injury, and the test sample can restore the secretory function of the gastric mucosa to a certain extent.

[0064] Table 4 Effects of samples on the incidence, integral index and inhibition rate of gastric mucosal injury in acute alcohol model

[0065] Group Injury incidence / % Points Index Inhibition rate / % Blank control group - <![CDATA[- ** ]]> - Model control group 100 17.63±10.46 - Low dose group 100 13.75±3.81 21.99％ Medium dose group 100 <![CDATA[9.88±3.18 ** ]]> 43.97％ High dose group 80 <![CDATA[2.50±1.51 ** ]]> 85.82％

[0066] Note: **P<0.01, compared with the model control group.

[0067] like Figure 1As shown in Table 4, the gastric mucosa of rats in the blank control group was smooth and pink, without congestion and erosion; ulcers appeared in the gastric mucosa of rats in the model control group, and the ulcer area was larger and involved the whole layer of gastric tissue; compared with the blank control group, the gastric mucosal injury index of rats in the model control group was significantly increased (P < 0.01); compared with the model control group, the gastric mucosal injury integral index of rats in the low-dose group did not change significantly, and that in the medium and high-dose groups was significantly decreased (P < 0.01), and with the increase of dose concentration, the inhibition rate increased, and the inhibition rate of the high-dose group reached 85.82%.

[0068] like Figure 2 As shown, the structures of each layer in the blank control group were clear, without cell degeneration and necrosis; no changes such as vascular congestion, hemorrhage and inflammatory cell infiltration were observed in the interstitium; pathological changes occurred in the glandular stomach mucosa of the model control group and the low-dose group, mainly degeneration and necrosis of the mucosal epithelium to varying degrees, congestion and hemorrhage of the vascular lamina propria, and atrophy of the mucosal layer; pathological changes occurred in part of the glandular stomach mucosa in the medium-dose group; and pathological changes occurred in a small part of the glandular stomach mucosa in the high-dose group.

[0069] Note: *P<0.05, **P<0.01, compared with the blank group; #P<0.05, compared with the model group.

[0070] Table 5 Histopathological scoring of samples for rats with acute alcohol model of gastric mucosal injury

[0071]

[0072] Based on the above pathological changes, the scores were statistically analyzed and compared. The results are shown in Table 5. The mean injury score of the blank control group was 0.00, and the mean injury score of the model control group was 9.40, which was significantly higher than that of the blank control group (P<0.05). Compared with the model group, the injury score of the low-dose group did not decrease. The injury scores of the medium-dose group and the high-dose group decreased, among which the high-dose group decreased most significantly (P<0.05).

[0073] In summary, the present application provides a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury and a preparation method thereof. The sea cucumber peptide for auxiliary protection of acute gastric mucosal injury prepared by the preparation method of the sea cucumber peptide for auxiliary protection of acute gastric mucosal injury is based on the established alcohol model of acute gastric mucosal injury, and the interleukin 1β (IL-1β), interleukin 6 (IL-6), pepsinogen 1 (PG1), pepsinogen 2 (PG2) and tumor necrosis factor α (TNF-α) in the serum of rats are detected and found to be significantly different from those in the control group. At the same time, through the effects on the incidence, integral index and inhibition rate of gastric mucosal injury in rats and the observation of pathological sections of gastric mucosal tissue, it can be seen that the sea cucumber peptide for auxiliary protection of acute gastric mucosal injury has an improvement effect on gastric mucosal injury in alcohol model rats, and the auxiliary protection function test results of gastric mucosal injury in alcohol model rats are positive, so the obtained sea cucumber peptide has an auxiliary protection function for gastric mucosal injury in alcohol model rats.

[0074] The "first", "second", "third", "fourth", etc. (if any) referred to in this application are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchangeable where appropriate, so that the embodiments described herein can be implemented in an order other than that illustrated or described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions, for example, a process, method, or device that includes a series of steps or units is not necessarily limited to those steps or units that are clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, or devices.

[0075] It should be noted that the descriptions involving "first", "second", etc. in this application are only used for descriptive purposes and cannot be understood as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Therefore, the features defined as "first" and "second" may explicitly or implicitly include at least one of the features. In addition, the technical solutions between the various embodiments can be combined with each other, but they must be based on the ability of ordinary technicians in the field to implement them. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by this application.

[0076] Specific examples are used herein to illustrate the principles and implementation methods of the present application. The description of the above embodiments is only used to help understand the method of the present application and its core idea. At the same time, for those skilled in the art, according to the idea of ​​the present application, there will be changes in the specific implementation methods and application scope. In summary, the content of this specification should not be understood as a limitation on the present application.

Claims

1. A method for preparing a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury, characterized in that: The steps include: Step 1, taking fresh sea cucumbers, washing, acid and alkali soaking, deashing and grinding treatment in sequence, to obtain sea cucumber grinding liquid; Step 2, boiling the sea cucumber grinding liquid at a constant temperature and pressure, cooling it to 55° C., and then performing enzymolysis with multiple complex enzymes to obtain an enzymolysis liquid; Step 3, heating the enzymatic hydrolyzate to 85°C and performing enzyme inactivation treatment for 5 minutes to obtain a protein peptide mixture; Step 4: Separate the protein peptides and obtain sea cucumber peptide particles by drying.

2. The method for preparing a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury according to claim 1, characterized in that: The cleaning is performed by washing with clean water, the acid-base deashing is performed by using an activated carbon acid-base deashing process, and the refining is performed by using a grinder.

3. The method for preparing a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury according to claim 1, characterized in that: The multiple complex enzyme comprises neutral protease, papain and trypsin; and the added mass ratio of the neutral protease, papain and trypsin is 0.6-1:1.2-2:

1.

4. The method for preparing a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury according to claim 1, characterized in that: The separation of protease comprises separating protein peptides by using a high-speed bedroom centrifuge.

5. The method for preparing a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury according to claim 1, characterized in that: The separation of protease also includes using a ceramic primary filtration membrane to coarsely filter visible solids and using an ultrafiltration membrane to separate macromolecular protein peptides.

6. The method for preparing a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury according to claim 1, characterized in that: The separation of protease and drying also include fermentation to remove fishy smell, heavy metal removal, desalination, small molecule peptide separation, decolorization and concentration treatment in sequence.

7. The method for preparing a sea cucumber peptide for auxiliary protection of acute gastric mucosal injury according to claim 1, characterized in that: The fermentation to remove fishy smell adopts a flavor fermentation process; the heavy metal removal and desalination adopt electrodialysis equipment to separate heavy metals and salts based on the electric field force or use ion exchange resin to remove heavy metals; the small molecule peptide separation adopts inorganic nanofiltration membrane to separate small molecule peptides below 1000DA; the decolorization adopts nanofiltration membrane for physical decolorization; the concentration adopts double-effect tank concentration, and the drying adopts centrifugal pressure spray drying tower for low-temperature spray drying.

8. A sea cucumber peptide for auxiliary protection of acute gastric mucosal injury, characterized in that: The sea cucumber peptide is prepared by the preparation method for auxiliary protection of acute gastric mucosal injury as described in any one of claims 1 to 7, and is used for auxiliary protection of acute gastric mucosal injury.

9. A sea cucumber peptide for auxiliary protection of acute gastric mucosal injury according to claim 8, characterized in that: The relative molecular mass of the amino acid sequence of sea cucumber peptide is 568.1.

Images